Myovant Sciences (Myovant Sciences) Days Sales Outstanding : 34.04 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Days Sales Outstanding?

Myovant Sciences's average Accounts Receivable for the three months ended in Dec. 2022 was $37.4 Mil. Myovant Sciences's Revenue for the three months ended in Dec. 2022 was $100.2 Mil. Hence, Myovant Sciences's Days Sales Outstanding for the three months ended in Dec. 2022 was 34.04.

The historical rank and industry rank for Myovant Sciences's Days Sales Outstanding or its related term are showing as below:

MYOV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.23 Med: 21.6 Max: 28.24
Current: 28.24

During the past 7 years, Myovant Sciences's highest Days Sales Outstanding was 28.24. The lowest was 21.23. And the median was 21.60.

MYOV's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 71.92 vs MYOV: 28.24

Myovant Sciences's Days Sales Outstanding increased from Dec. 2021 (27.92) to Dec. 2022 (34.04).

Myovant Sciences Days Sales Outstanding Historical Data

The historical data trend for Myovant Sciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Days Sales Outstanding Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Days Sales Outstanding

Get a 7-Day Free Trial

21.97

21.23

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Days Sales Outstanding	Get a 7-Day Free Trial															27.92	33.45	20.74	27.60	34.04

Competitive Comparison of Myovant Sciences's Days Sales Outstanding

For the Biotechnology subindustry, Myovant Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Days Sales Outstanding falls into.

Myovant Sciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Myovant Sciences's Days Sales Outstanding for the fiscal year that ended in Mar. 2022 is calculated as

	Days Sales Outstanding (A: Mar. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2021 )	+	Accounts Receivable (A: Mar. 2022 ))	/	count )	/	Revenue (A: Mar. 2022 )	*	Days in Period
=	( (3.57	+	23.296)	/	2 )	/	230.972	*	365
=	13.433					/	230.972	*	365
=	21.23

Myovant Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding (Q: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2022 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (33.762	+	41.021)	/	2 )	/	100.229	*	365 / 4
=	37.3915					/	100.229	*	365 / 4
=	34.04

Myovant Sciences (NYSE:MYOV) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Myovant Sciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957